Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04KJT
|
|||
| Former ID |
DCL001131
|
|||
| Drug Name |
ABT-333
|
|||
| Synonyms |
Dasabuvir; 1132935-63-7; ABT-333; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; ABT333; UNII-DE54EQW8T1; ABT 333; Dasabuvir (ABT-333); DE54EQW8T1; CHEBI:85182; N-(6-(3-tert-Butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide; C26H27N3O5S; Dasabuvir [INN]; N-{6-[3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl]naphthalen-2-yl}methanesulfonamide; Dasabuvir [USAN:INN]; Dasabuvir (USA
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [1] | |
| Company |
Abbott
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H27N3O5S
|
|||
| Canonical SMILES |
CC(C)(C)C1=CC(=CC(=C1OC)C2=CC3=C(C=C2)C=C(C=C3)NS(=O)(=O)C)N4C=CC(=O)NC4=O
|
|||
| InChI |
1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31)
|
|||
| InChIKey |
NBRBXGKOEOGLOI-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1132935-63-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:85182
|
|||
| ADReCS Drug ID | BADD_D00588 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Abbott Laboratories (2011) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.